The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Trial watch: Chemotherapy with immunogenic cell death inducers
Open accessAbstract
Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs, including conventional chemotherapeutics as well as targeted anticancer agents, originates (at least in part) from their ability to elicit a novel or reinstate a pre-existing tumor-specific immune response. One of the mechanisms whereby chemotherapy can stimulate the immune system to recognize and destroy malignant cells is commonly known as immunogenic cell death (ICD). Cancer cells succumbing to ICD are de facto converted into an anticancer vaccine and as such elicit an adaptive immune response. Several common chemotherapeutics share the ability of triggering ICD, as demonstrated in vaccination experiments relying on immunocompetent mice and syngeneic cancer cells. A large number of ongoing clinical trials involve such ICD inducers, often (but not always) as they are part of the gold standard therapeutic approach against specific neoplasms. In this Trial Watch, we summarize the latest advances on the use of cyclophosphamide, doxorubicin, epirubicin, oxaliplatin, and mitoxantrone in cancer patients, discussing high-impact studies that have been published during the last 13 months as well as clinical trials that have been initiated in the same period to assess the antineoplastic profile of these immunogenic drugs as off-label therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–219 of 219
Phase I clinical trial combining imatinib mesylate and IL-2
Chaput, N., Flament, C., Locher, C., Desbois, M., Rey, A., Rusakiewicz, S., Poirier-Colame, V., Pautier, P., Cesne, A. L., Soria, J., et al. (2013) · OncoImmunology · doi:10.4161/onci.23080 · Cited by 28
Self-citationRustin, G. J. S., Reed, N. S., Jayson, G. C., Ledermann, J. A., Adams, M., Perren, T. J., Poole, C. J., Lind, M., Persic, M., Essapen, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq780 · Cited by 28
Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy
Ma, Y., Yamazaki, T., Yang, H., Kepp, O., Galluzzi, L., Zitvogel, L., Smyth, M. J., & Kroemer, G. (2013) · OncoImmunology · doi:10.4161/onci.24786 · Cited by 27
Self-citationLee, K., Park, S. R., Oh, D., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0032-y · Cited by 26
The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors
Schreiber, T. H. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0396 · Cited by 26
Molinari, R., D’Eliseo, D., Manzi, L., Zolla, L., Velotti, F., & Merendino, N. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1074-7 · Cited by 25
7A7 MAb: A New Tool for the Pre-Clinical Evaluation of EGFR-Based Therapies
Garrido, G., Sanchez, B., Rodriguez, H. M., Lorenzano, P., Alonso, D. F., & Fernandez, L. E. (2004) · Hybridoma and Hybridomics · doi:10.1089/1536859041224280 · Cited by 24
An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
Senovilla, L., Vitale, I., Martins, I., Kepp, O., Galluzzi, L., Zitvogel, L., Castedo, M., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.22409 · Cited by 24
Self-citationDocetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer
Lauro, L. D., Vici, P., Belli, F., Tomao, S., Fattoruso, S. I., Arena, M. G., Pizzuti, L., Giannarelli, D., Paoletti, G., Barba, M., et al. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0321-3 · Cited by 24
Chacon, J. A., Pilon‐Thomas, S., Sarnaik, A. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.25581 · Cited by 24
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients
Pautier, P., Locher, C., Robert, C., Deroussent, A., Flament, C., Cesne, A. L., Rey, A., Bahleda, R., Ribrag, V., Soria, J., et al. (2013) · OncoImmunology · doi:10.4161/onci.23079 · Cited by 23
Self-citationSchmudde, M., Friebe, E., Sonnemann, J., Beck, J. F., & Bröker, B. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.024 · Cited by 22
Kim, Y. S., Sym, S. J., Park, S. H., Park, I., Hong, J., Ahn, H. K., Park, J., Cho, E. K., Lee, W. K., Chung, M., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2334-3 · Cited by 19
Following up tumor-specific regulatory T cells in cancer patients
Zitvogel, L., Tanchot, C., Granier, C., & Tartour, É. (2013) · OncoImmunology · doi:10.4161/onci.25444 · Cited by 19
Self-citationMavilio, D., & Lugli, E. (2013) · OncoImmunology · doi:10.4161/onci.26535 · Cited by 18
Chemotherapy and Immunomodulation: From Immunogenic Chemotherapies to Novel Therapeutic Strategies
Ghiringhelli, F., & Apétoh, L. (2013) · Future Oncology · doi:10.2217/fon.12.207 · Cited by 13
Park, S. R., Hong, Y. S., Lim, H., Seong, M., Kong, S., Kim, S. Y., Park, Y., & Jung, K. H. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2272-0 · Cited by 12
Raez, L. E., Santos, E. S., Webb, R. T., Wade, J. L., Brito, R. A., Karr, M., Kennah, A., & Childs, B. H. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2301-z · Cited by 11
Yang, L., Song, Y., Zhou, A., Qin, Q., Chi, Y., Huang, J., & Wang, J. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20131009 · Cited by 8
Cited by
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Self-citationMlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Self-citationThe Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Self-citation
Metadata
- Authors
- Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2013-03
- Volume
- 2
- Issue
- 3
- Pages
- e23510
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2031659092
- Cited by
- 265
- References
- 219
- FWCI
- 22.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.